ERAL1 and breast cancer: Human estrogen receptor alpha (hERα or ER-α66) is a variant of ER that is predominantly expressed in BC [3] compared to the Erβ isoform; therefore, it is a critical target in the assessment of prognosis [6] and the design of a BC therapy strategy.